Perspective Therapeutics, Inc. Common Stock CATX 深 滬
已收盤 08-01 16:00:00 美东时间
3.68
-0.160
-4.17%
華盛通- 最 高3.83
- 今 開3.78
- 成交量 68.69万股
- 最 低 3.65
- 昨 收 3.84
- 總市值 2.73亿
- 52周最高 16.55
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 1.60
- 委 比 -47.39%
- 總股本 7422.83万
- 歷史最高 37.90
- 量 比 1.03
- 振 幅 4.69%
- 歷史最低 1.60
- 每 手 1
- 風險率 4.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Perspective Therapeutics Updates Radiopharmaceutical Platform Presentation
Perspective Therapeutics ( ($CATX) ) just unveiled an announcement. On August 1...
08-02 04:29
Perspective Therapeutics To Present Updated [212Pb]VMT-α-NET Cancer Therapy Data At ESMO Congress 2025
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the
07-25 00:46
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
Perspective Therapeutics announced updated data on their [212Pb]VMT-α-NET program for advanced somatostatin receptor 2 positive neuroendocrine tumors, accepted for presentation at the ESMO Congress 2025 in Berlin. The presentation, titled "Safety and efficacy of [212Pb]VMT-α-NET in SSTR2+ NETs," will feature mature safety and preliminary efficacy results from 44 patients in dose-finding cohorts 1 and 2. The therapy uses 212Pb alpha particles to t...
07-24 16:45
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer diagnoses are climbing fastest...
07-23 21:26
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
Perspective Therapeutics, Inc. (NYSE American: CATX), a radiopharmaceutical company, announced it will report Q2 2025 financial results and provide a business update on August 13, 2025. The press release will be available on their website. The company specializes in advanced cancer treatments using alpha-emitting isotope 212Pb and is developing theranostic approaches combining imaging and therapy to improve treatment efficacy. Their programs for ...
07-15 11:00
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to c...
06-25 00:52
美股大行评级 | 买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元
买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元>>
06-24 10:07
Perspective Therapeutics Advances Phase 1/2a Clinical Trial
Perspective Therapeutics ( ($CATX) ) has provided an announcement. On June 21, ...
06-24 02:23
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target
Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
06-23 21:40
